NCT03505736View on ClinicalTrials.gov

Stress Test in Detecting Heart Damage in Premenopausal Women With Stage I-III Breast Cancer

CompletedOBSERVATIONAL
Enrollment

25

Participants

Timeline

Start Date

June 21, 2018

Primary Completion Date

March 5, 2020

Study Completion Date

March 5, 2020

Conditions
Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage IA Breast Cancer AJCC v8Anatomic Stage IB Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Anatomic Stage IIB Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8PremenopausalPrognostic Stage I Breast Cancer AJCC v8Prognostic Stage IA Breast Cancer AJCC v8Prognostic Stage IB Breast Cancer AJCC v8Prognostic Stage II Breast Cancer AJCC v8Prognostic Stage IIA Breast Cancer AJCC v8Prognostic Stage IIB Breast Cancer AJCC v8Prognostic Stage III Breast Cancer AJCC v8Prognostic Stage IIIA Breast Cancer AJCC v8Prognostic Stage IIIB Breast Cancer AJCC v8Prognostic Stage IIIC Breast Cancer AJCC v8
Interventions
BIOLOGICAL

Adenosine

Given IV

PROCEDURE

Magnetic Resonance Imaging

Undergo CMR imaging

DRUG

Regadenoson

Given IV

PROCEDURE

Stress Management Therapy

Undergo stress test

Trial Locations (1)

27157

Wake Forest University Health Sciences, Winston-Salem

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Wake Forest University Health Sciences

OTHER

NCT03505736 - Stress Test in Detecting Heart Damage in Premenopausal Women With Stage I-III Breast Cancer | Biotech Hunter | Biotech Hunter